百洋医药
(301015)
| 流通市值：130.65亿 | | | 总市值：130.67亿 |
| 流通股本：5.26亿 | | | 总股本：5.26亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,840,874,860.51 | 8,094,458,068.74 | 6,143,923,658.27 | 3,594,708,467.52 |
| 营业收入 | 1,840,874,860.51 | 8,094,458,068.74 | 6,143,923,658.27 | 3,594,708,467.52 |
| 二、营业总成本 | 1,635,496,471.03 | 7,169,337,235.28 | 5,252,717,606.61 | 3,123,535,308.65 |
| 营业成本 | 1,181,508,227.26 | 5,220,659,643.58 | 3,949,547,752.4 | 2,461,447,859.51 |
| 税金及附加 | 9,296,766.43 | 43,955,505.47 | 33,609,944.23 | 19,005,898.55 |
| 销售费用 | 351,371,788.98 | 1,516,920,293.54 | 1,004,773,583.96 | 517,949,170.25 |
| 管理费用 | 65,412,264.55 | 280,553,399.49 | 188,040,855.15 | 97,525,401.52 |
| 研发费用 | 5,426,988.5 | 36,139,782.22 | 19,683,970.5 | - |
| 财务费用 | 22,480,435.31 | 71,108,610.98 | 57,061,500.37 | 27,606,978.82 |
| 其中:利息费用 | 21,627,783.41 | 80,092,315.85 | 59,592,537.61 | 33,388,841.31 |
| 其中:利息收入 | 3,106,272.37 | 13,635,219.99 | 12,645,973.37 | 7,621,120.59 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -24,154,284.33 | 1,715,871.08 | -6,134,974.03 | -2,409,124.63 |
| 加:投资收益 | -8,918,355.5 | 59,209,403.06 | 37,980,848.89 | 22,642,396.93 |
| 资产处置收益 | 18,355.17 | 925,017.58 | 641,077.55 | 178,011.28 |
| 资产减值损失(新) | -34,185,911.73 | -16,023,077.4 | -8,591,452.29 | -9,392,353.23 |
| 信用减值损失(新) | -5,369,154.04 | -11,827,892.28 | -12,826,425.8 | -9,424,603.48 |
| 其他收益 | 12,442,301.19 | 18,617,808.51 | 9,194,702.62 | 4,284,547.03 |
| 四、营业利润 | 145,211,340.24 | 977,737,964.01 | 911,469,828.6 | 477,052,032.77 |
| 加:营业外收入 | 29,201.34 | 2,432,118.77 | 434,883.28 | 299,421.79 |
| 减:营业外支出 | 1,986,431.98 | 13,542,466 | 3,987,761.05 | 2,866,373.41 |
| 五、利润总额 | 143,254,109.6 | 966,627,616.78 | 907,916,950.83 | 474,485,081.15 |
| 减:所得税费用 | 33,591,209.61 | 199,596,972.39 | 217,340,597.15 | 108,443,856.83 |
| 六、净利润 | 109,662,899.99 | 767,030,644.39 | 690,576,353.68 | 366,041,224.32 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 109,662,899.99 | 767,030,644.39 | 690,576,353.68 | 366,041,224.32 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 85,012,813.37 | 691,593,321.92 | 640,996,996.58 | 368,689,315.45 |
| 少数股东损益 | 24,650,086.62 | 75,437,322.47 | 49,579,357.1 | -2,648,091.13 |
| 扣除非经常损益后的净利润 | 99,966,953.05 | 655,947,072.73 | 610,308,847.57 | 370,758,786.33 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 1.32 | 1.22 | 0.7 |
| (二)稀释每股收益 | 0.16 | 1.28 | 1.18 | 0.68 |
| 八、其他综合收益 | 628,024.82 | -104,993.07 | -1,596,916.54 | -1,140,551.27 |
| 归属于母公司股东的其他综合收益 | 570,184.82 | -178,040.99 | -1,547,112.34 | -1,170,251.71 |
| 九、综合收益总额 | 110,290,924.81 | 766,925,651.32 | 688,979,437.14 | 364,900,673.05 |
| 归属于母公司股东的综合收益总额 | 85,582,998.19 | 691,415,280.93 | 639,449,884.24 | 367,519,063.74 |
| 归属于少数股东的综合收益总额 | 24,707,926.62 | 75,510,370.39 | 49,529,552.9 | -2,618,390.69 |
| 公告日期 | 2025-04-24 | 2025-04-24 | 2024-10-26 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |